Steven N Hart
Overview
Explore the profile of Steven N Hart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
5677
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang H, Hu C, Na J, Hart S, Gnanaolivu R, Abozaid M, et al.
Nature
. 2025 Jan;
638(8050):528-537.
PMID: 39779857
Germline BRCA2 loss-of function variants, which can be identified through clinical genetic testing, predispose to several cancers. However, variants of uncertain significance limit the clinical utility of test results. Thus,...
2.
Albayrak A, Xiao Y, Mukherjee P, Barnett S, Marcou C, Hart S
J Pathol Inform
. 2024 Dec;
16:100409.
PMID: 39720417
With the increasing utilization of exome and genome sequencing in clinical and research genetics, accurate and automated extraction of human phenotype ontology (HPO) terms from clinical texts has become imperative....
3.
Gnanaolivu R, Hart S
Comput Struct Biotechnol J
. 2024 Oct;
23:3472-3480.
PMID: 39430403
Background: The loss-of-function (LOF) classification of most missense variants in tumor suppressor breast cancer genes , and remains unclassified and confounds clinical actionability. Classifying these variants is challenging due to...
4.
Akamandisa M, Boddicker N, Yadav S, Hu C, Hart S, Ambrosone C, et al.
medRxiv
. 2024 Oct;
PMID: 39417132
Importance: Pathogenic variants (PVs) in , and are associated with increased breast cancer risk. However, it is unknown whether breast cancer risk differs by PV type or location in carriers...
5.
Cecchini M, Borowitz M, Glassy E, Gullapalli R, Hart S, Hassell L, et al.
Arch Pathol Lab Med
. 2024 Sep;
149(2):142-151.
PMID: 39343982
Context.—: Generative artificial intelligence (AI) technologies are rapidly transforming numerous fields, including pathology, and hold significant potential to revolutionize educational approaches. Objective.—: To explore the application of generative AI, particularly...
6.
Zanti M, OMahony D, Parsons M, Dorling L, Dennis J, Boddicker N, et al.
medRxiv
. 2024 Sep;
PMID: 39281752
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating...
7.
Fasching P, Hu C, Hart S, Ruebner M, Polley E, Gnanaolivu R, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):57.
PMID: 39003306
Germline mutations in BRCA1 and BRCA2 (gBRCA1/2) are required for a PARP inhibitor therapy in patients with HER2-negative (HER2-) advanced breast cancer (aBC). However, little is known about the prognostic...
8.
Gu Q, Patel A, Hanna M, Lennerz J, Garcia C, Zarella M, et al.
Arch Pathol Lab Med
. 2024 Jun;
149(3):276-287.
PMID: 38871349
Context.—: Computational pathology combines clinical pathology with computational analysis, aiming to enhance diagnostic capabilities and improve clinical productivity. However, communication barriers between pathologists and developers often hinder the full realization...
9.
Flotte T, Derauf S, Byrd R, Kroneman T, Bell D, Stetzik L, et al.
Arch Pathol Lab Med
. 2024 Apr;
149(1):55-59.
PMID: 38649149
Context.—: Artificial intelligence is a transforming technology for anatomic pathology. Involvement within the workforce will foster support for algorithm development and implementation. Objective.—: To develop a supportive ecosystem that enables...
10.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...